The 3 most recent market catalysts affecting $NAMS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 85
NewAmsterdam Pharma Receives Marketing Authorization From European Commission For Ubeslo, Evlarco To Treat Primary Hypercholesterolaemia
NewAmsterdam Pharma has received marketing authorization from the European Commission for Ubeslo and Evlarco, two non-statin medicines for primary hypercholesterolaemia. This is a …
Sep 8, 2026
Market Technicals
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target
HC Wainwright & Co. analyst Lander Egaña Gorroño has reaffirmed a 'Buy' rating and a $52 price target for NewAmsterdam Pharma Co (NAMS). This action signals that the analyst's inve…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 92
NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate
NewAmsterdam Pharma's Q2 earnings report reveals a mixed financial performance. The company's earnings per share (EPS) of $(0.52) significantly missed analyst estimates and showed …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.